Loading
Thomas Lynch is a lung cancer oncologist who co-discovered EGFR mutations and now leads Fred Hutch.
Thomas Lynch Jr. is President and Director of Fred Hutchinson Cancer Center, a role he has held since 2020, having previously led Yale Cancer Center and Massachusetts General Hospital's cancer centre. A thoracic oncologist specialising in lung cancer and targeted therapy, his 2004 New England Journal of Medicine paper identified EGFR mutations as the reason some lung cancers respond to gefitinib. His papers include that report of activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib and the BMS099 phase III trial of cetuximab with first-line taxane and carboplatin chemotherapy in advanced non-small-cell lung cancer. His work links EGFR and small-molecule kinase inhibitors to cancer centre leadership.
| Title | Journal | Year |
|---|---|---|
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | New England Journal of Medicine | 2004 |
| Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 | Journal of Clinical Oncology | 2010 |
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR, Small-molecule kinase inhibitors.
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
Shares Fred Hutchinson Cancer Center, Non-small-cell lung cancer.
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR, Small-molecule kinase inhibitors.
Shares Fred Hutchinson Cancer Center, Non-small-cell lung cancer.
Shares Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR, Small-molecule kinase inhibitors.